The novel anti-influenza virus agent baloxavir marboxil is a selective inhibitor of an influenza capdependent endonuclease. Although a single oral dose in tablet form of baloxavir marboxil is expected to improve drug compliance and rapidly reduce viral titers for pediatric patients with influenza, there is a concern that baloxavir marboxil-resistant influenza A variants could be generated. In this study, we investigated the frequency of prescription and pharmacy revisits for baloxavir marboxil at an outpatient clinic compared with that of neuraminidase inhibitors in pediatric patients with influenza. A total of 475 pediatric patients who were infected with the influenza virus visited the pharmacy between December 2019 and March 2020. Baloxavir marboxil (n 149), oseltamivir (n 161) and laninamivir (n 162) were mainly prescribed and only a few patients were treated with peramivir (n 2) or zanamivir (n 1). Baloxavir marboxil-, oseltamivir-and laninamivir-treated pediatric patients were enrolled, and a log-rank test showed that the revisits of pediatric patients who were taking baloxavir marboxil was lower than those for oseltamivir (p < 0.001). Moreover, Cox proportional hazards models also revealed that baloxavir marboxil decreased the risk of revisits in comparison to oseltamivir (hazard ratio 0.28, 95% confidence interval 0.11-0.70, p 0.006), while no difference was found between laninamivir and baloxavir marboxil. Although there is a need to acquire appropriate and relevant information concerning resistant viruses, our results suggest that baloxavir marboxil may be a useful drug for treating pediatric patients with influenza infections.
: The present study sought to compare the effectiveness of a proton pump inhibitor PPI with that of a histamine H 2 receptor antagonist H2RA for treating functional dyspepsia FD in a real-world setting. A multicenter, open-label, randomized trial was conducted. FD patients were randomly assigned to receive either 20 mg, q.d., omeprazole OPZ ; a PPI or 150 mg, b.i.d., ranitidine hydrochloride RAN ; an H2RA for 4 weeks. Any change in the total Gastrointestinal Symptom Rating Scale GSRS score delta at week 4 was the primary outcome measure. Secondary outcome measures were reductions in scores for individual items on the GSRS at week 4. As a subanalysis, patients were strati ed according to Helicobacter pylori serology and the analyses were repeated. The mean SD deltas in total GSRS score for the OPZ and RAN groups were 0.8 0.7 and 0.6 0.6, respectively P 0.098 ; however, the delta in re ux score between the OPZ and RAN groups differed signi cantly 1.1 0.7 vs. 0.5 0.5, respectively ; P 0.001 . There were no significant differences between the two groups in any other scores for individual items on the GSRS. The results of the subanalysis were like those of the main analysis. The PPI and H2RA produced a comparable improvement in symptoms of FD in our patient cohort, thus we propose no advantage would be gained in using a PPI rather than an H2RA.
A 44‐year‐old man presented to our hospital with lower gastrointestinal bleeding. We performed balloon‐assisted enteroscopy, which revealed diverticulum and stricture at the ileum. The patient underwent segmental small bowel resection and diagnosed with Meckel's diverticulum. We should keep in mind the possibility of intestinal stricture due to Meckel's diverticulum.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.